<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190667</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-HRD</org_study_id>
    <nct_id>NCT04190667</nct_id>
  </id_info>
  <brief_title>Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer</brief_title>
  <official_title>A Study on the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The homologous recombination deficiency (HRD) status in Chinese population with epithelial
      ovarian cancer (EOC) is little known. This study would recruit 1300 Chinese EOC patients. A
      multi-panel testing of 36 genes would be given for these patients in their peripheral blood
      and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1,
      BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL,
      MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2,
      MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or
      likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further
      explore the HRD status. The HRD model is based on the loss of heterozygosity (LOH), telomere
      allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score
      model and their relationship with the prognosis, would provide a full description of for the
      Chinese EOC patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2019</start_date>
  <completion_date type="Anticipated">December 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of targeted genetic mutations</measure>
    <time_frame>Two years</time_frame>
    <description>Frequency of pathogenic or likely pathogenic mutations in a multi-panel genes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Homologous recombination deficiency (HRD) score</measure>
    <time_frame>Two years</time_frame>
    <description>The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for three types of important molecular mechanism: loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Two years</time_frame>
    <description>Progression-free survival in recruited patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Two years</time_frame>
    <description>Overall survival in recruited patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sensitivity to platinum-based chemotherapy</measure>
    <time_frame>Two years</time_frame>
    <description>Sensitivity to platinum-based chemotherapy in recruited patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sensitivity to poly-(ADP-ribose) polymerase inhibitors</measure>
    <time_frame>Two years</time_frame>
    <description>Sensitivity to poly-(ADP-ribose) polymerase inhibitors in recruited patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Chinese</condition>
  <condition>Homologous Recombination Deficiency</condition>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <condition>Prognosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genomic testing</intervention_name>
    <description>A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples from the patients' peripheral blood and tumor tissues.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese population with confirmed diagnosis of epithelial ovarian cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Pathological confirmation of epithelial ovarian cancer

          -  With available tumor tissues

          -  Given consents to participate the study

        Exclusion Criteria:

          -  Not meeting all of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Wu</last_name>
    <phone>+8613810224549</phone>
    <email>wuming@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

